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Abstract
Background: Adiponectin is an adipose tissue derived hormone which strengthens insulin sensitivity. However, there is little
data available regarding the influence of a positive energy challenge (PEC) on circulating adiponectin and the role of obesity
status on this response.
Objective: The purpose of this study was to investigate how circulating adiponectin will respond to a short-term PEC and
whether or not this response will differ among normal-weight(NW), overweight(OW) and obese(OB).
Design: We examined adiponectin among 64 young men (19-29 yr) before and after a 7-day overfeeding (70% above
normal energy requirements). The relationship between adiponectin and obesity related phenotypes including; weight,
percent body fat (%BF), percent trunk fat (%TF), percent android fat (%AF), body mass index (BMI), total cholesterol, HDLc,
LDLc, glucose, insulin, homeostatic model assessment insulin resistance (HOMA-IR) and b-cell function (HOMA-b) were
analyzed before and after overfeeding.
Results: Analysis of variance (ANOVA) and partial correlations were used to compute the effect of overfeeding on
adiponectin and its association with adiposity measurements, respectively. Circulating Adiponectin levels significantly
increased after the 7-day overfeeding in all three adiposity groups. Moreover, adiponectin at baseline was not significantly
different among NW, OW and OB subjects defined by either %BF or BMI. Baseline adiponectin was negatively correlated
with weight and BMI for the entire cohort and %TF, glucose, insulin and HOMA-IR in OB. However, after controlling for
insulin resistance the correlation of adiponectin with weight, BMI and %TF were nullified.
Conclusion: Our study provides evidence that the protective response of adiponectin is preserved during a PEC regardless
of adiposity. Baseline adiponectin level is not directly associated with obesity status and weight gain in response to short-
term overfeeding. However, the significant increase of adiponectin in response to overfeeding indicates the physiological
potential for adiponectin to attenuate insulin resistance during the development of obesity.
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Introduction
The accumulation of white adipose tissue (WAT) is the product
of a chronic positive energy balance in an obesogenic environment
[1]. Numerous disorders such as insulin resistance, type 2 diabetes
(T2D) and cardiovascular disease have shown a strong association
with the accumulation of subcutaneous and visceral fat mass [2,3].
Once regarded as a site for energy storage, recent research has
shown that WAT secretes a large number of physiologically active
proteins [4,5,6] thus playing an integral role in human endocri-
nology and energy homeostasis [7,8,9]. Adiponectin, for example,
is predominantly secreted into circulation from adipose tissue,
which increases insulin sensitivity resulting in the effective disposal
of glucose from circulation [10,11,12]. Accumulating evidence
suggests that adiponectin is strongly associated with glucose and
lipid metabolism, although adiponectin’s role in the development
of obesity and insulin resistance remains unclear.
Considering that adiponectin has been recognized as a
significant insulin sensitizer it would be consistent to anticipate
that circulating adiponectin levels would be considerable in the
presence of an insulin resistant state such as obesity. However, the
puzzling actuality suggests that adiponectin is inversely associated
with obesity [13,14,15,16,17,18] and insulin resistance
[16,19,20,21]. Consequently if adiponectin is an anti-obesigenic
and anti-diabetic protein, expected to increase in circulation, it is
perplexing that adiponectin levels are attenuated in both obese
and diabetic populations. Nevertheless there is significant evidence
that adiponectin does indeed play a beneficial role in both lipid
and glucose metabolism [20,21,22,23]. Rodent studies have shown
that adiponectin gene knockout mice severely attenuate glucose
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disposal and [20,23] the administration of adiponectin can
effectively ameliorate insulin resistance [21,22]. These findings
demonstrate that adiponectin can protect or even reverse obesity
related disease states. However, the paradoxical inverse relation-
ship of adiponectin with adiposity remains unclear.
Our laboratory and others have demonstrated that a short-term
positive energy challenge affects glucose and lipid metabolism,
which results in significant body weight gain and insulin resistance
[1,24,25,26,27]. Moreover, changes in nutritional status have also
shown to significantly affect circulating adipokines [1,24,27]. For
this reason we propose that investigating the response of
adiponectin, to adiposity development, will provide insight into
the potential role that adiponectin may play in the development of
obesity and diabetes. The objective of our present investigation is
to address the following as yet unanswered question: Does
circulating adiponectin increase in response to a short-term
positive energy challenge and is this potential response obesity
status dependent. To our knowledge this is the first study of its kind
to investigate the effect of a 7-day positive challenge (70% above
normal energy requirements) on circulating adiponectin among
normal-weight, overweight and obese individuals.
Methods
Ethics Statement
This study was approved by The Health Research Ethics
Authority (HREA) for the Faculty of Medicine, Memorial
University of Newfoundland and Labrador, St John’s, Canada.
All subjects provided written informed consent. Initial data
collection for this study began October 2003.
Subjects
Sixty-four young men, recruited from the city of St. John’s
(Newfoundland and Labrador, Canada) and surrounding areas,
participated in the current positive energy challenge (PEC) study.
The study inclusion criteria were as follows: 1) male; 2) non-
smoker, 3) 19–29 yr of age; 4) at least third-generation New-
foundlander; 5) healthy young men, without any serious metabolic,
cardiovascular, or endocrine disease; 6) not receiving medication
for lipid metabolism; 7) reported stable weight (62.5 kg) in the
previous 6 months and 8) subjects abstained from any alcoholic or
additional calorie-containing beverage consumption during the
study period. Participants refrained from taking any drugs/
medications throughout the duration of the study. All physical
and biochemical measurements were collected, after a 12 hour
fast, on the morning of the first day of overfeeding and one day
after the 7th and final day of overfeeding. Study participants were
free living throughout the experiment and were not restricted to an
experimental environment, such as a hospital.
Serum measurements
Fasting blood samples were obtained from all subjects before
and after the completion of the overfeeding intervention. Serum
was stored at –80uC for subsequent analyses. The majority of
biochemical markers [28] and adiponectin [29] remain stable
under these storing conditions. Adiponectin (Phoenix Pharmaceu-
ticals, Belmont, California) concentrations were measured in
duplicate utilizing enzyme-linked immunosorbent assays. The
intra-assay variation ranged from 4.8 – 5.4% and the inter-assay
variation was 5.1%. The detection limit of the adiponectin ELISA
kits used was 0. 15 ng/ml when using 100 mL diluted samples.
Serum insulin concentrations were measured with the use of an
immunoassay analyzer (Immulite; DPC, Los Angeles, CA). The
homeostasis model assessment (HOMA) was used as a measure of
insulin resistance and beta cell function [30].
HOMA{IR~((Fasting Insulin½mU=ml|
Fasting Glu cos e½mmol=L)=22:5)
HOMA{b~((20|Fasting Insulin½mU=ml=
(Fasting Glu cos e½mmol=L{3:5))
Serum concentrations of glucose, triacylglycerols (TG), high-
density lipoprotein (HDLc) cholesterol and total cholesterol were
measured by an Lx20 analyzer (Beckman Coulter Inc, Fullerton,
CA). Low-density lipoprotein (LDLc) cholesterol was calculated as
seen below. The LDL cholesterol calculation is reliable in the
absence of severe hyperlipidemia.
LDLc~½Total Cholesterol(mmol=L){
HDL Cholesterol(mmol=L){
(Triacy lg lycerol(mmol=L)=2:2)
Body composition measurements
Height (nearest 0.1 cm) and weight (nearest 0.1 kg) measure-
ments were collected and Body Mass Index (BMI) calculated. BMI
was defined as weight divided by height squared (kg/m2). Percent
body fat (%BF), percent trunk fat (%TF), and percent android
(abdominal) fat (%AF), were measured utilizing dual-energy X-ray
absorptiometry (DXA, Lunar Prodigy; GE Medical Systems,
Madison, WI). Measurements were performed on subjects in a
supine position, after the removal of all metal accessories [1,31].
Version 12.2 of the enCORE (enCORE,Ver 12.2, 2008, GE
Medical Systems, Madison, WI) software package was used for
DXA analysis. DXA measurements (fat weight, lean tissue weight
and bone weight) are recorded to the nearest 0.001 kg.
Overfeeding protocol
Participants consumed 70% more calories than their normal
energy requirements (hypercaloric), which consisted of 15%
protein, 35% fat, and 50% carbohydrates to mimic the common
daily diet in North America. Baseline energy requirements were
determined from three 24-hr diet recalls and a 30-d dietary
inventory. The average caloric intake per day was as follows:
energy (baseline: 2969 kcal; overfeeding: 5471 kcal), protein
(baseline: 106 g; overfeeding: 178 g), carbohydrates (baseline:
394 g; overfeeding: 713 g), fiber (baseline: 19 g; overfeeding:
33 g), total fat (baseline: 105 g; overfeeding: 221 g), saturated fat
(baseline: 38 g; overfeeding: 71 g), and cholesterol (baseline:
304 mg; overfeeding: 735 mg). Subjects were offered meals at
0900, 1200, and 1700h every day, and energy values and
macronutrient content of the food were measured by using
FOOD PROCESSOR SQL software (version 9.5.0.0; ESHA
Research, Salem, OR). The actical physical activity monitor (Mini
Mitter Co, Inc, Bend, OR) was used to determine the total energy
expenditure. Physical activity levels were controlled below 15%
between the baseline and overfeeding period. Full details of our
overfeeding protocol have been previously described and all of the
participants in this study were members of these studies [1,24,25].
On average, subjects gained 2.261.4 kg body weight, of which
44.1630.4% (0.842 kg60.531) was body fat. A 7-day overfeeding
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protocol, 70% above normal energy requirements, was chosen for
this study to ensure that the intervention would induce metabolic
changes. [1,24,25].
Statistical analysis
Data are presented as means 6 SDs unless otherwise stated.
Before any statistical analysis was performed, data that were not
normally distributed were logarithmically transformed (TG,
insulin, HOMA-IR and HOMA-b) to approximate normal
distribution. Sixty-four young men were used for the analysis of
this paper. Subjects were classified on the basis of %BF as normal
weight (8 – 20.9%), overweight (21 – 25.9%) or obese (. 26%)
according to criteria recommended by Bray [32]. Statistical
analysis was also performed on adiposity groups classified by BMI
according to the WHO criteria [33]. To further explore the
relationship between adiponectin and body composition, partic-
ipants were divided into tertiles according to baseline fasting serum
adiponectin concentrations (mg/ml) as follows: Low (Bottom
33.3%), Medium (middle 33.3%) and High (top 33.3%) adipo-
nectin concentration. The range of serum adiponectin at baseline
for the Low, Medium and High adiponectin concentration groups
were 1.60–8.15 mg/ml, 8.20–13.80 mg/ml, and14.20–27.10 mg/
ml respectively.
Differences in variables between the three adiposity groups in
response to overfeeding were analyzed by using a mixed model
repeated two-way analysis of variance. Baseline values between the
three adiposity groups were analyzed using a one-way analysis of
variance. The Bonferroni post-hoc test was run after the one-way
ANOVA and the two-way ANOVA displaying a significant
overfeeding by adiposity interaction. Within group analysis on the
response to overfeeding was performed with a student paired t-test
on variables that displayed a significant overfeeding by adiposity
interaction effect. Pearson’s correlation analyses were performed
to screen for potential factors related to fasting adiponectin
concentrations followed by partial correlation analyses after
controlling for age. Bonferroni testing was applied to correct for
multiple comparisons. Two correlation analyses were performed
as follows: 1) adiponectin at baseline was compared with all
variables at baseline; and 2) adiponectin at baseline was compared
with changes in all variables in response to overfeeding to
investigate whether baseline adiponectin could predict the changes
in related markers. SPSS software version 18.0 (SPSS Inc,
Chicago, IL, USA) was used for all analyses. Statistical analyses
were 2-sided and p,0.05 was considered to be statistically
significant.
Results
Comparison of characteristics at baseline and in response
to short-term overfeeding
Physical and biochemical characteristics of subjects at baseline
are shown in Table 1. Fasting serum adiponectin concentrations
at baseline for normal weight (11.6066.3 mg/ml), overweight
(12.8464.6 mg/ml) and obese (10.6966.3 mg/ml) subjects were
not significantly different from one another. Adiponectin concen-
trations were also analyzed according to BMI criteria where no
significant differences were found (data not shown).
Changes in body composition and phenotypes of glucose
metabolism and lipids in response to the 7-day overfeeding are
also described in Table 1. The 7-day positive energy challenge
protocol significantly increased subcutaneous body fat, serum
lipids (except LDL cholesterol), insulin resistance and b cell
function. The only significant overfeeding x adiposity status
interactions found from our analysis were for %BF and %TF,
indicating that normal weight subjects experienced a greater
significant increase in body fat percentage than overweight and
obese (Table 1). The analysis of variance revealed that
adiponectin concentrations were significantly increased due to
the 7-day positive energy challenge (p,0.0001). Fasting adipo-
nectin levels increased by 18.9% within the entire cohort after
overfeeding while increasing by 20.3%, 15.4% and 19.9% among
normal-weight, overweight and obese young men respectively.
With a ,19% change in adiponectin due to overfeeding with 64
subjects the calculated power was 0.81.
Correlations of adiponectin with phenotypes of glucose
and lipid metabolism
Correlations between baseline adiponectin and baseline pheno-
types were assessed (Table 2). In the entire cohort at baseline,
adiponectin was negatively correlated with weight and BMI along
with a positive correlation with HDLc. However, when these
analyses were repeated according to adiposity status no correlation
between adiponectin and these variables were found. In addition,
when insulin and HOMA-IR were controlled for during partial
correlation analysis on the entire cohort the relationship between
adiponectin with weight and BMI were nullified. Adiponectin was
significantly inversely correlated with %TF, glucose, insulin, and
HOMA-IR in the obese group. Correlations between baseline
adiponectin and the changes in phenotypes were also assessed to
determine if adiponectin could act as a predictor of these
parameters under conditions of an energy surplus (Table 3).
Only two significant negative correlations between baseline
adiponectin and the change in phenotypes due to overfeeding
were found among the adiposity groups. The first inverse
relationship was found between adiponectin and insulin in the
normal weight group and the second inverse relationship was
found between adiponectin and triacyglycerol in the obese group.
Comparison of body composition and lipid profile
measures in low, medium and high baseline fasting
serum adiponectin concentrations
Lastly, we wanted to investigate the relationship between low,
medium, and high baseline fasting serum adiponectin concentra-
tions and markers for lipids and body composition. The between
group comparison at baseline demonstrated that there were no
significant differences in body composition measurements among
the low, medium and high adiponectin concentration groups.
Total %BF stratified in the low, medium, and high adiponectin
concentrations were 23.969.4%, 21.968.4% and 22.8566.8%
respectively (p = 0.735). BMI values at baseline were also not
significantly different among the low, medium, and high
adiponectin concentrations groups. It would seem that only
HDL cholesterol was significantly different between the low and
medium (p= 0.044) as well as the low and high (p = 0.01) baseline
adiponectin concentration groups. The two-way ANOVA re-
vealed that the 7-day overfeeding effectively increased whole
adiponectin concentrations (p,0.0001) and in addition that there
was a significant overfeeding by adiponectin concentration group
interaction (p= 0.002). Sub-group analysis revealed that adipo-
nectin significantly increased within the low baseline adiponectin
group from 5.3962.0 mg/ml to 9.1163.75 mg/ml (p,0.001) and
the medium baseline adiponectin group from 10.6161.7 mg/ml to
13.0563.1 mg/ml (p,0.001), but did not significantly increase
within the high baseline adiponectin group (18.2463.6 mg/ml to
18.7162.8 mg/ml).
Adiponectin and Nutritional Regulation
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Discussion
The noteworthy finding of the present investigation is that
circulating adiponectin levels are significantly increased by a short-
term positive energy challenge independent of adiposity status.
Taking into consideration that the majority of human cross-
sectional studies show that circulating adiponectin is diminished
among the obese population [13,14,15,16], and significantly
promoted after weight reduction [15,19,34,35], the increase in
circulating adiponectin we observed after weight gain in
overweight and obese subjects was unexpected. White adipose
tissue being the primary location for the adiponectin production,
together with the paradoxical inverse relationship between
adiponectin and obesity, advocates that circulating adiponectin
may be regulated by an adiposity feedback inhibition [15]. Rodent
studies, observing a suppression of adiponectin in obese and ob/ob
mice [21,36,37], support the notion of an adiposity regulated
feedback mechanism. However adiponectin transgenic ob/ob
mice effectively ameliorating insulin resistance but not obesity
[38,39] and adiponectin knockout mice developing insulin
resistance without affecting weight or adiposity [20,23], provides
the strongest evidence that adiponectin is not mediated by
adiposity alone. In addition, the administration of adiponectin to
ob/ob, db/db, and adiponectin knockout mice can ameliorate the
development of insulin resistance without significantly influencing
adiposity [21,22]. In the present study adiponectin concentration
significantly increased within the entire cohort and the normal-
weight, overweight, and obese subgroups due to overfeeding.
However, there was no significant difference in the increase of
circulating adiponectin between the three obesity groups due to
overfeeding. To further explore this unique finding we stratified
our subjects into a low, medium and high adiponectin concentra-
tion groups to determine whether adiponectin concentration was
associated with the increase in adiposity due to the positive energy
challenge. Consequently, there was no significant difference in the
increase of our adiposity measurements among adiponectin
concentration groups before or after overfeeding. These findings
would suggest that there is a definite capacity, regardless of obesity
status, for the human body to significantly synthesize and secrete
more adiponectin into circulation after being exposed to a short-
term overfeeding. To our knowledge this is the first study of its
kind to demonstrate that adiponectin levels will significantly
increase after a short-term positive energy challenge independent
of obesity status.
Our laboratory has demonstrated that a short-term positive
energy challenge can significantly affect both physical and
biochemical obesity-related phenotypes [1,24,25]. However, to
date, very few other overfeeding studies have been performed due
to the inherent difficulty to carry out this type of study. One 5-day
high-fat (60% fat, 32.5% carbohydrates and 7.5% protein)
overfeeding (50% greater than normal caloric intake) investigation
on 26 normal-weight young men observed a significant increase in
adiponectin concentration [27]. Although the age and body weight
of these subjects were comparable to the normal-weight group
Table 1. Physical and biochemical characteristics of subjects at baseline and in response to 7-days of overfeeding1.
Normal Weight2 Overweight2 Obese2
(n=23 – 25) (n =13 – 14) (n=22 – 25)
Before After Before After Before After
Age (y) 23.9 6 3.7 NA 22.0 6 3.1 NA 23.2 6 2.4 NA
Height (cm) 178.9 6 6.6 NA 179.6 6 4.8 NA 179.6 6 7.1 NA
Weight (kg) 4,5,6 72.3 6 9.6 74.4 6 9.6 77.8 6 4.3 79.4 6 4.3 91.4 6 15.4 93.9 6 16.0
BMI (kg/m2) 4,5,6 22.6 6 2.7 23.2 6 2.9 24.1 6 1.3 24.6 6 1.5 28.2 6 4.2 29.1 6 4.3
Percent Body Fat (%) 3,5,6,7 14.82 6 3.4 15.60 6 3.4 8 22.54 6 0.8 22.82 6 1.1 8 31.15 6 4.9 31.01 6 4.8
Percent Trunk Fat (%) 3,5,6,7 16.78 6 3.7 17.78 6 3.8 8 25.39 6 1.9 25.79 6 2.2 8 35.07 6 5.4 34.97 6 5.3
Percent Android Fat (%) 3,5,6 19.38 6 4.4 20.16 6 5.0 28.84 6 2.6 29.45 6 2.7 40.00 6 7.2 40.77 6 6.8
Total Cholesterol (mmol/L) 5 4.41 6 0.9 4.68 6 0.9 4.63 6 0.9 4.72 6 1.1 4.59 6 0.7 4.86 6 0.8
HDL-Cholesterol (mmol/L) 5 1.38 6 0.3 1.48 6 0.3 1.38 6 0.3 1.43 6 0.3 1.12 6 0.2 1.34 6 0.3
LDL-Cholesterol (mmol/L) 2.61 6 0.7 2.64 6 0.7 2.82 6 0.7 2.83 6 0.9 2.81 6 0.7 2.83 6 0.6
Triacylglycerol (mmol/L) 5,6 0.94 6 0.3 1.22 6 0.8 0.92 6 0.3 1.00 6 0.5 1.35 6 0.7 1.57 6 0.9
Glucose (mmol/L) 4.98 6 0.4 5.03 6 0.5 5.03 6 0.4 5.09 6 0.6 5.24 6 0.7 5.11 6 0.5
Insulin (pmol/L) 4,5,6 44.22 6 23.8 64.02 6 23.7 51.54 6 17.03 68.69 6 43.6 80.19 6 53.3 108.2 6 76.7
HOMA-IR 4,5,6 1.43 6 0.8 2.09 6 0.9 2.35 6 2.68 2.95 6 2.9 2.80 6 2.3 3.67 6 2.8
HOMA-b 4,5,6 85.45 6 39.38 126.3 6 49.9 101.49 6 25.1 140.8 6 101.7 134.95 6 63.0 190.3 6 107.3
Adiponectin (mg/mL) 5 11.6 6 6.3 13.96 6 4.5 12.84 6 4.6 14.81 6 4.05 10.69 6 6.3 12.82 6 6.1
1All values are means 6 SDs. HOMA - IR, Homeostasis model assessment of insulin resistance; HOMA - b of b cell function; NA, not applicable.
Adiposity status and response to overfeeding analyzed by 2 - factor mix model ANOVA (SPSS, version 17.0 Chicago, IL, USA) for repeated measures.
2Subjects were classified on the basis of %BF as either normal weight (8 – 20.9%), overweight (21 – 25.9%) or obese (. 26%) according to criteria recommended by Bray
[32].
3Significant difference between normal weight, overweight and obese subjects at baseline (1 - Way ANOVA, followed by a Bonferroni corrected test, P,0.05).
4Significant difference between normal weight vs obese subjects at baseline (1 - Way ANOVA, followed by a Bonferroni corrected test, P,0.05).
5Significant difference due to overfeeding (2 - Way mixed model ANOVA, P,0.05).
6Significant difference due to adiposity status (2 - Way mixed model ANOVA, P,0.05).
7Significant overfeeding by adiposity status interaction (2 - Way mixed model ANOVA, followed by a Bonferroni corrected test when significant, P,0.05).
8Significant difference within group (paired t-test, P,0.05).
doi:10.1371/journal.pone.0074215.t001
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from our current study, the overfeeding intervention and diet
composition were considerable different. This study also did not
contain any overweight and/or obese subjects. Nevertheless our
findings, with those of Bron et al. [27], provides evidence that the
significant increase of adiponectin due to overfeeding is likely
driven by an increase in total caloric intake rather than
macronutrient composition. A 4-week positive energy challenge
on 18 young normal-weight adults (12 male and 6 female) did not
induce a significant increase in circulating adiponectin [40].
Although no explanation was provided, low statistical power due
Table 3. Partial correlations of changes in variables due to overfeeding related to baseline fasting serum adiponectin, after control
for age1.
All Subjects Normal weight2 Overweight2 Obese2
(n=59 – 64) (n =23 – 25) (n =14) (n =22 – 25)
r p r p r p r p
Weight –0.043 NS 0.015 NS –0.103 NS –0.049 NS
BMI –0.045 NS 0.011 NS –0.103 NS –0.050 NS
Percent Body Fat 0.066 NS 0.155 NS –0.415 NS –0.027 NS
Percent Trunk Fat 0.101 NS 0.158 NS –0.248 NS 0.183 NS
Percent Android Fat –0.123 NS –0.191 NS –0.244 NS –0.057 NS
Total Cholesterol 0.053 NS 0.146 NS 0.326 NS –0.069 NS
HDL-Cholesterol –0.086 NS 0.05 NS –0.073 NS –0.115 NS
LDL-Cholesterol 0.168 NS 0.241 NS 0.439 NS –0.040 NS
Triacylglycerols –0.142 NS –0.035 NS –0.430 NS –0.435 0.0383
Glucose –0.045 NS –0.264 NS 0.095 NS 0.002 NS
Insulin –0.125 NS –0.438 0.0323 0.313 NS 0.112 NS
HOMA-IR –0.084 NS –0.175 NS 0.059 NS 0.230 NS
HOMA-Beta –0.081 NS –0.298 NS 0.210 NS 0.099 NS
1HOMA-IR, Homeostasis model assessment of insulin resistance; HOMA-b of b cell function. Partial correlation analysis after control for age was used to screen for the
potential changes in factors due to overfeeding related to fasting adiponectin.
2Subjects were classified on the basis of %BF as either normal weight (8–20.9%), overweight (21–25.9%) or obese (.26%) according to the Bray criteria [32].
3Not significant after Bonferroni correction to adjust for the multiple variables tested.
doi:10.1371/journal.pone.0074215.t003
Table 2. Partial correlations of baseline variables related to baseline fasting serum adiponectin, after control for age1.
All Subjects Normal weight2 Overweight2 Obese2
(n=59 – 64) (n=23 – 25) (n =14) (n =22 – 25)
r p r p r p r p
Weight –0.246 0.0503 –0.284 NS –0.425 NS –0.177 NS
BMI –0.289 0.0233 –0.322 NS –0.188 NS –0.296 NS
Percent Body Fat –0.127 NS –0.094 NS 0.338 NS –0.309 NS
Percent Trunk Fat –0.155 NS –0.096 NS 0.235 NS –0.403 0.0413
Percent Android Fat –0.140 NS 0.064 NS 0.066 NS –0.343 NS
Total Cholesterol 0.057 NS 0.340 NS 0.050 NS –0.313 NS
HDL-Cholesterol 0.401 0.001 0.178 NS 0.222 NS 0.357 NS
LDL-Cholesterol 0.020 NS 0.328 NS –0.039 NS –0.242 NS
Triacylglycerols –0.175 NS 0.089 NS 0.167 NS –0.339 NS
Glucose –0.225 NS 0.196 NS 0.026 NS –0.427 0.0423
Insulin –0.225 NS 0.126 NS –0.192 NS –0.499 0.0153
HOMA-IR –0.229 NS 0.141 NS –0.170 NS –0.505 0.0143
HOMA-Beta –0.204 NS 0.042 NS –0.292 NS –0.399 NS
1HOMA-IR, Homeostasis model assessment of insulin resistance; HOMA-b of b cell function. Partial correlation analysis after control for age was used to screen for the
potential changes in factors due to overfeeding related to fasting adiponectin.
2Subjects were classified on the basis of %BF as either normal weight (8–20.9%), overweight (21–25.9%) or obese (.26%) according to the Bray criteria [32].
3Not significant after Bonferroni correction to adjust for the multiple variables tested.
doi:10.1371/journal.pone.0074215.t002
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to the small number of subjects could be a potential reason.
Finally, a long-term (100-day) overfeeding study investigated the
influence of chronic food intake on circulating adiponectin in 12
pairs of young male identical twins [41]. Study participants were
overfed by 840 kcal for 100 days and adiponectin concentration
was found to have decreased. However there was no relationship
between baseline adiponectin and adiposity before or after
prolonged overfeeding. A replication study would be favored
since this is the only long-term positive energy challenge study
containing a fairly small sample size. Overall, the current human
overfeeding studies demonstrate that adiponectin concentrations
are up regulated during a short-term positive energy challenge.
Our findings would suggest that adiponectin plays a protective role
during obesity development and its role is more potent during the
early stages of the chronic positive energy balance. This
assumption is supported by data from an animal experiment
which found that circulating adiponectin concentrations signifi-
cantly increased in C57BL/6J mice on a high-fat diet during the
initial stages of adiposity development [42] and decreased after the
full 18 week diet.
The present investigation did not find a significant difference in
baseline adiponectin concentration among normal-weight, over-
weight and obese subjects nor were any associations found
between adiponectin concentration and adiposity measurements
for these groups. In addition, no significant difference was
observed for any body composition measurement among the
low, medium and high adiponectin concentration groups. The
data from this investigation does not support the hypothesis that
adiposity status is a strong contributing factor to circulating
adiponectin concentration. We did observe that circulating
adiponectin was inversely correlated with BMI and weight for
the entire cohort along with %TF in obese subjects. However,
recent studies have advocated that the inverse relationship
between adiponectin and adiposity phenotypes is solely dependent
upon the development of insulin resistance [10,13,17,43]. There-
fore, after controlling for fasting insulin and/or HOMA-IR in our
analysis the significant partial correlation between adiponectin and
aforementioned body composition measurements were nullified.
Therefore, our data supports the hypothesis that the paradoxical
relationship between adiposity and circulating adiponectin is not
dependent upon the accumulation of adipose tissue but rather the
concomitant increase in insulin resistance during obesity develop-
ment [17,18,43].
The primary limitation of the present study is that we only
studied young males (19–29 yr), which limits the application of our
conclusions to other groups. Larger population studies investigat-
ing the effects of overfeeding on a wider age distribution which
includes females is warranted. In addition, only total circulating
adiponectin was measured in this investigation. It has been
suggested that high molecular weight adiponectin is the primary
physiologically active isoform [44] of adiponectin. However, it has
also been shown that low, medium and high molecular weight
adiponectin respond to nutritional regulation and exercise the
same as total circulating adiponectin [34]. In addition, the
influence of inflammatory markers (such as TNF-a, IL-6 and hs-
CRP, etc.) on adiponectin regulation is a noteworthy consideration
[45]. Therefore, future short-term overfeeding studies investigating
influence of inflammatory markers on the regulation and
circulation of adiponectin in adipose tissue and peripheral
circulation are warranted.
In summary, we investigated the response of circulating
adiponectin to a 7-day positive energy challenge mimicking a
North American diet in 64 healthy young men. The relationship
between adiponectin and adiposity status was also analyzed. The
current study revealed that endogenous adiponectin concentration
significantly increased within the entire cohort and all three
adiposity groups in response to short-term overfeeding. Fasting
serum adiponectin levels were found to be similar among normal-
weight, overweight and obese young men at baseline and were not
associated with adiposity. Negative correlations of adiponectin
with %TF, body weight and BMI was observed, but likely
arbitrated to insulin resistance. Our data suggests for first time that
the increase in adiponectin, in the face of short-term positive
energy challenge, may act as a protective mechanism during
periods of weight gain against insulin resistance independent of
adiposity status and diet composition.
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